Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial was to evaluate efficacy and safety of adding Rituximab to
dose-dense and High-Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT)
as first line treatment in young patients with DLBCL at Intermediate-High and High risk aaIPI
score
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie